Doxycycline

For research use only.

Catalog No.S5159 Synonyms: Vibramycin, Doxytetracycline, Doxiciclina, Doxycyclinum

11 publications

Doxycycline Chemical Structure

CAS No. 564-25-0

Doxycycline (Vibramycin, Doxytetracycline, Doxiciclina, Doxycyclinum) is an antibiotic that is used in the treatment of a number of types of infections caused by bacteria and protozoa. Doxycycline is also a nonspecific matrix metalloproteinase (MMP) inhibitor.

Size Price Stock Quantity  
EUR 95 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Doxycycline has been cited by 11 publications

Purity & Quality Control

Choose Selective Antineoplastic and Immunosuppressive Antibiotics Inhibitors

Biological Activity

Description Doxycycline (Vibramycin, Doxytetracycline, Doxiciclina, Doxycyclinum) is an antibiotic that is used in the treatment of a number of types of infections caused by bacteria and protozoa. Doxycycline is also a nonspecific matrix metalloproteinase (MMP) inhibitor.
In vitro

100 ng/mL-5 µg/mL Dox can significantly alter the metabolic profile of the cell, as well as reduce the proliferative rate, though the effect size depends upon the particular cell line used[1]. Doxycycline arrests cells in G1-S phase of the cell cycle in PANC-1 cells and induces the expression of p53 and its downstream target p21. It down-regulates antiapoptotic genes and induces proapoptotic genes. Doxycycline also induces apoptosis through a Fas/Fas-ligand dependent pathway in Jurkat T lymphocytes[2].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Staphylococcus aureus 2 planktonic cells NVzQ[5NwSmGldHXybYNq\GGuIHHzd4F6 MV2yOEBpenN? M1HxfmJi[3SncnnjbYRidCCjY4Tpeol1gSCjZ3HpcpN1KG2ndHjpZ4ltdGmwLYLld4l{fGGwdDDTeIFxcHmub3PvZ4N2eyCjdYLleZMhOiCybHHub5RwdmmlIHPlcIx{KGGodHXyJFI1KGi{czDifUBk[WypYYL5JIJqd2[rbH2g[IV3cWOnIH3leIhw\CxiTVLDQVLPxE1w MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTZ|OEGyNUc,Ojl4M{ixNlE9N2F-
THP1 NUPNSVdLTnWwY4Tpc44h[XO|YYm= NFy5dnRU\WynY4Tpeol1gSCrbnTlfEwhemG2aX:gc4YhUUN3MDDmc5IhcHWvYX6gWGhROSClZXzsd{B1dyCLQ{WwJIZweiCSbHHzcY9lcXWvIH\hcINqeGG{dX2sJGlEPTB;Mz6x{txONg>? MlzqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl5NEi3PFEoRjF7N{S4O|gyRC:jPh?=
K562 MmnOR5l1d3SxeHnjbZR6KGG|c3H5 NEe1eIY4OiCqcoO= NUm0OnlTS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUzV4MjDj[YxteyCjZoTldkA4OiCqcoOgZpkh\myxdzDjfZRwdWW2comsJGlEPTB;MUZOwG0v MnT3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl2OEK0O|YoRjF7NEiyOFc3RC:jPh?=
K562 MVHDfZRwfG:6aXPpeJkh[XO|YYm= MkT5O|IhcHK| M{mzOmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGs2PjJiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JIZtd3diY4n0c41mfHK7LDDJR|UxRTF3zszNMi=> NF7Ee|I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUmyOlE4Oyd-MUm5NlYyPzN:L3G+
HepG2 MWfDfZRwfG:6aXPpeJkh[XO|YYm= NUPXW4lKPzJiaILz NXHvdVBSS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWyR{KgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0zOM7:TT6= NVjzZZRKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm0PFI1PzZpPkG5OFgzPDd4PD;hQi=>
HepG2 MnrPR5l1d3SxeHnjbZR6KGG|c3H5 M2DYb|czKGi{cx?= NVjSR2dqS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWyR{KgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0zOM7:TT6= NXf1OW42RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm5NlYyPzNpPkG5PVI3OTd|PD;hQi=>
THP1 NH6xfoFEgXSxdH;4bYNqfHliYYPzZZk> MY[3NkBpenN? M{D6TWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHRJWDFiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JJBzd3CrZHn1cUBqd2SrZHWgd5RicW6rbnetZoF{\WRiZnzve{BkgXSxbXX0dpktKEmFNUC9NlDPxE1w NUfTW3lnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3OFg4QDFpPkG5O|Q5PzhzPD;hQi=>
HepG2 MX;DfZRwfG:6aXPpeJkh[XO|YYm= MV23NkBpenN? M4LjU2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmeEd{IHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEOFNUC9NlDPxE1w NIj4WGc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUe0NVE{OSd-MkG3OFEyOzF:L3G+
HepG2 MUnDfZRwfG:6aXPpeJkh[XO|YYm= MmPBO|IhcHK| Mli2R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVxTzJiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhS0N3ME2yNO69VS5? NXjIcmU2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4PFk2PTlpPkKyPFg6PTV7PD;hQi=>
HepG2 MkTWR5l1d3SxeHnjbZR6KGG|c3H5 MkThO|IhcHK| NXnDc5dHS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWyR{KgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiQ1O1NF0zOM7:TT6= MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTh3MkGzNkc,OjF6NUKxN|I9N2F-
HepG2 NGLsRVJEgXSxdH;4bYNqfHliYYPzZZk> NIjmcnE4OiCqcoO= NYDKWZdoS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWyR{KgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiQ1O1NF0zOM7:TT6= NW\SUIJNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OFYzOTZpPkK0PVQ3OjF4PD;hQi=>
HepG2 MkiwR5l1d3SxeHnjbZR6KGG|c3H5 NVzTfHdYPzJiaILz M{nNd2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmeEd{IHPlcIx{KGG|c3Xzd4VlKGG|IHPlcIwhfmmjYnnsbZR6KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEOFNUC9NlDPxE1w NGLCeVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe5NVY4PSd-MkW3PVE3PzV:L3G+
HepG2 MoT1R5l1d3SxeHnjbZR6KGG|c3H5 MUG3NkBpenN? NVPWUo5[S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWyR{KgZ4VtdHNiaX7jeYJifGWmIH\vdkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCFQ{WwQVIx|ryPLh?= MnPwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{OEKyOlcoRjJ3MkiyNlY4RC:jPh?=
HepG2 M2\Ob2N6fG:2b4jpZ4l1gSCjc4PhfS=> NYnrbGhjPzJiaILz MkPMR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVxTzJiY3XscJMhdWWjc4Xy[YQh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhS0N3ME2yNO69VS5? NYTld3VyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexOVU1PjNpPkK3NVU2PDZ|PD;hQi=>
HepG2 MXTDfZRwfG:6aXPpeJkh[XO|YYm= MXS3NkBpenN? MoL4R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVxTzJiY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFPDOVA:OjEQvF2u MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzZ3NEO5OUc,Ojd4NUSzPVU9N2F-
SW1353 MlfySpVv[3Srb36gZZN{[Xl? MW[1NEB2VQ>? MkHZTY5pcWKrdHnvckBw\iCLTD2xMYJmfGFvaX7keYNm\CCPTWCxN{Bxem:mdXP0bY9vKGmwIHj1cYFvKFOZMUO1N{Bk\WyuczDheEA2OCC3TR?= M{LhfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5Mk[3NlI4Lz5zN{K2O|IzPzxxYU6=
K-12 BW25113 M1XSPGJi[3SncnnjbYRidCCjc4PhfS=> Mk\jNlQhcHK| MWTCZYN1\XKrY3nkZYwh[WO2aY\peJkh[WejaX7zeEB6[W[TIHflcoUu\GWoaXPp[Y51KEW|Y3jldolkcGmjIHPvcIkhUy1zMjDCW|I2OTF|IHLpc4ZqdG1iYYPz[ZN{\WRiYYOgcI9oKHKnZIXjeIlwdiCxZjD2bYFjdGViY3XscJMh[W[2ZYKgNlQhcHK| M3KwUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7M{C3N|c2Lz5zOUOwO|M4PTxxYU6=
K-12 BW25113 NInLbY1D[WO2ZYLpZ4ll[WxiYYPzZZk> NGPPRVAzPCCqcoO= NVrMcWFxSmGldHXybYNq\GGuIHHjeIl3cXS7IHHnZYlve3RiRYPjbIVzcWOqaXGgZ49tcSCNLUGyJGJYOjVzMUOgZolw\mmubTDoZZJjd3KrbnegdGNCOjSQIID0ZYM7QnmjZmGgdIxie22rZDDhd5Nme3OnZDDhd{Btd2dicnXkeYN1cW:wIH;mJJZq[WKuZTDj[YxteyCjZoTldkAzPCCqcoOgdJJmfHKnYYTl[EB4cXSqIEWgeW0hd2ZiSWDUS{Bnd3JiNDDodpM> M2rVVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7M{C3N|c2Lz5zOUOwO|M4PTxxYU6=
Neuro2a NUPNdpVUTnWwY4Tpc44h[XO|YYm= NYDPTZFlOSC3TR?= MXXE[YNz\WG|ZTDpckA4NUSKQzDs[ZZmdHNiaX6gSIhkejdvZHXmbYNq\W62IH3veZNmKE6ndYLvNoEh[2WubIOgZZQhOSC3TTDifUBNSy2PUz;HR{1OWyCjbnHsfZNqew>? MknqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5OEm2OVcoRjJ4N{i5OlU4RC:jPh?=
vascular endothelial cells NELFfYdCdnSrYnHjeIVzcWGuIHHzd4F6 NYLLepRYOjVidXevcYw> NEXPSHU4OiCqcoO= NXnsTHhUSW62aXLhZ5RmemmjbDDhZ5Rqfmm2eTDh[4FqdnO2IGLpZ4tmfHS|aXGgdJJwf2G8ZXvpbUB{fHJwIFLy[YlvdCCrbn\lZ5Rm\CCrbjDDSEBz[XRicILpcYFzgSCydXztc45ienlidnHzZ5Vt[XJiZX7kc5Rp\WyrYXygZ4VtdHNiYYPz[ZN{\WRiYYOgZoFkfGW{aXHsJJNp[XCnIHPoZY5o\SCjdDCyOUB2\y:vbDDt[YF{fXKnZDC3NkBpenNicH;zeEBqdm[nY4Tpc44h[nliSH;lZ4h{fCB|M{K1PE9xcGGubH;p[IlvKHO2YXnubY5oKGKjc3XkJIZtfW:{ M4fucVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MEi5N|UxLz5{OEC4PVM2ODxxYU6=
A673 NFn3O5lyUFSVIHHzd4F6 NYjwOWVCeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFG2O|Mh[2WubIO= MnjyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
BT-12 NFLscHNyUFSVIHHzd4F6 NIHPcY1yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQmStNVIh[2WubIO= M3vONFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Hep2 NEPXOpRCdnSrLVPocIFugWSrYXygZZN{[Xl? NHXNdHEyKHWpL33s MW[4JIhzew>? NIfYVmpCdnSrLVPocIFugWSrYXygZYN1cX[rdImgZYdicW6|dDDDbIxidXmmaXGgeJJi[2ixbXH0bZMhW2W{b4\hdkBNT1ZvTEKgbY5n\WO2ZXSgbY4hUGWyMjDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4he2m8ZTDhcoQhdnWvYnXyJI9nKGOqbHHtfYRq[WxiaX7jcJV{cW:wIHH0JFEhfWdxbXygeJJm[XSnZDDheEA5KGi{czDwc5N1NWmwZnXjeIlwdiCjbnSgNlQhcHK|IHzheIVzKHKnLXnu[oVkfGmwZzDmdoV{cCCKZYCyJINmdGy|IH3vco9t[Xl? Mn:0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzJ{Mke5OFgoRjN{MkK3PVQ5RC:jPh?=
skeletal myoblast cells NH73e49EgXSxdH;4bYNqfHliYYPzZZk> NX;5UGE2TE6GSUqgR5l1d3SxeHnjbZR6KGmwIG\peJJwNCB5MjDoc5VzNCCrbjDyZZQhe2unbHX0ZYwhdXmxYnzhd5Qh[2WubIOsJGlEPTB;MUSuOFnPxE1w NIHU[Vg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDN|Lze+R4hGVUKOPD;hQi=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
AKT / BCL6 / Cyclin E / HDAC2 / HDAC3 / NEMO / TYK2 / RIPK1 ; 

PubMed: 26142707     


Doxycycline treatment decreases the levels of HSP90 client proteins in DLBCL cells. The DLBCL cells were treated with the indicated concentrations of doxycycline for 24 hrs. The levels of HSP90 client proteins in these cells were analyzed by western blotting.

HSP70 / HSP90 ; 

PubMed: 26142707     


Reduced protein levels of HSP70 and HSP90 in DLBCL cells treated with doxycycline. DLBCL cells were treated with doxycycline for 24 hrs, and the levels of HSP70 and HSP90 were analyzed by western blotting. 

pATM / ATM ; 

PubMed: 23282955     


Levels of phosphorylated ATM and overall ATM was determined in the indicated cell lines at the indicated times after treatment with 1μg/ml doxycycline, as detected by Western Blotting.

26142707 23282955
Immunofluorescence
E-cadherin / Vimentin ; 

PubMed: 29285218     


Doxycycline increases E-cadherin expression and decreases Vimentin expression, whereas thrombin partly counteracts this inhibitory effect in MCF-7 cells.

29285218
In vivo Doxycycline successfully reduces tumor growth in vivo (inhibited pancreatic cancer cell growth)[2].

Protocol

Cell Research:

[1]

- Collapse
  • Cell lines: U87 astrocytoma cells, lung cancer cell lines H157 and H1437, LNCaP prostate cancer and HeLa cervical cancer cell lines
  • Concentrations: 100 ng/mL, 1 µg/mL
  • Incubation Time: 24, 72, and 96 hours
  • Method:

    Cells are seeded in 6 well plates at 50,000 cells per well and treated with Dox (100 ng/mL, 1 µg/mL, or vehicle control). Cells are counted 24, 72, and 96 hours after plating using a particle counter.


    (Only for Reference)

Solubility (25°C)

In vitro DMSO 88 mg/mL (198.0 mM)
Ethanol '-1 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 444.43
Formula

C22H24N2O8

CAS No. 564-25-0
Storage powder
in solvent
Synonyms Vibramycin, Doxytetracycline, Doxiciclina, Doxycyclinum
Smiles CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04686799 Not yet recruiting Drug: Doxycycline Hyclate 20 MG Lateral Epicondylitis|Lateral Epicondylitis Left Elbow|Lateral Epicondylitis Right Elbow|Lateral Epicondylitis Unspecified Elbow|Lateral Epicondylitis (Tennis Elbow) Bilateral Hospital for Special Surgery New York January 2021 Phase 2|Phase 3
NCT04597424 Not yet recruiting Drug: Experimental: doxycycline|Biological: Bexsero® vaccine Unsafe Sex|Risk-Taking French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) December 2020 Phase 3
NCT04269434 Recruiting Other: No Screening Neisseria Gonorrhoeae Infection|Chlamydia Trachomatis Infection Institute of Tropical Medicine Belgium September 21 2020 Not Applicable
NCT03709459 Recruiting Drug: Doxycycline STIs Prevention Kirby Institute|South Australian Health and Medical Research Institute|Monash University December 17 2019 --
NCT03558984 Recruiting Drug: D-PLEX|Other: Standard of Care Surgical Site Infection|Sternal Infection|Cardiac Surgery PolyPid Ltd. December 17 2019 Phase 3
NCT03194204 Completed Drug: Doxycycline Tablets Rheumatoid Arthritis Assiut University October 1 2019 Not Applicable

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field
Tags: buy Doxycycline | Doxycycline supplier | purchase Doxycycline | Doxycycline cost | Doxycycline manufacturer | order Doxycycline | Doxycycline distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID